STOCK TITAN

Tang Capital group reports 6.6% Capricor (NASDAQ: CAPR) ownership on Schedule 13G

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Tang Capital Management and related entities have disclosed a significant ownership position in Capricor Therapeutics, Inc. common stock. The group reports beneficial ownership of 3,399,900 shares of Capricor common stock, representing 6.6% of the outstanding shares as of the referenced date. All 3,399,900 shares are reported with shared voting and shared dispositive power, and no shares are reported with sole voting or dispositive power.

Within the group, Tang Capital Partners, LP reports 2,337,350 shares, or 4.5% of the class, and Tang Capital Partners International, LP reports 1,062,550 shares, or 2.1% of the class. Kevin Tang is identified as sharing voting and dispositive power with the Tang Capital entities. The filing is made on Schedule 13G, and the reporting persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Capricor Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI") and Kevin Tang. The percentages used herein are based on 51,716,975 shares of Common Stock outstanding as of December 8, 2025, as set forth in the Prospectus Report filed on Form 424(b)(5) that was filed with the Securities and Exchange Commission on December 5, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI and TCM.


SCHEDULE 13G




Comment for Type of Reporting Person: TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person: TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



TANG CAPITAL MANAGEMENT, LLC
Signature:/s/ Kevin Tang
Name/Title:Manager
Date:01/26/2026
KEVIN TANG
Signature:/s/ Kevin Tang
Name/Title:Self
Date:01/26/2026
TANG CAPITAL PARTNERS, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:01/26/2026
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:01/26/2026
TANG CAPITAL PARTNERS III, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:01/26/2026
TANG CAPITAL PARTNERS IV, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:01/26/2026

FAQ

What ownership stake in Capricor Therapeutics (CAPR) does Tang Capital report?

Tang Capital Management and related entities report beneficial ownership of 3,399,900 shares of Capricor Therapeutics common stock, representing 6.6% of the outstanding shares.

Which entities are included in the Tang Capital reporting group for CAPR?

The reporting group includes Tang Capital Management, LLC, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., Tang Capital Partners IV, Inc., and Kevin Tang.

How many CAPR shares are reported by Tang Capital Partners, LP and Tang Capital Partners International, LP?

Tang Capital Partners, LP reports 2,337,350 shares (4.5% of the class), and Tang Capital Partners International, LP reports 1,062,550 shares (2.1% of the class).

Does Tang Capital have sole or shared voting power over its CAPR shares?

The group reports 0 shares with sole voting or dispositive power and 3,399,900 shares with shared voting and shared dispositive power.

Is Tang Capital’s CAPR ownership reported as a passive investment?

Yes. The reporting persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Capricor Therapeutics.

What reference share count is used to calculate Tang Capital’s 6.6% ownership of CAPR?

The 6.6% figure is based on 51,716,975 shares of Capricor common stock outstanding as of December 8, 2025, as cited from a Form 424(b)(5) prospectus.

Capricor Therapeutics Inc

NASDAQ:CAPR

CAPR Rankings

CAPR Latest News

CAPR Latest SEC Filings

CAPR Stock Data

1.28B
44.04M
16.79%
30.53%
25.14%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO